Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to commercial manufacturing for small molecules and biologics. It also manufactures and sells specialized fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company was incorporated in 2006 and is based in Bengaluru, India.
| Current Price | ₹800.75 |
|---|---|
| Market Cap | ₹46,303 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 77.5 |
| Return on Equity | 19.45% |
| 52-Week Range | ₹579.15 – ₹977.55 |
| Beta (1Y) | 0.53 |
| Dividend Yield | 0.25% |
| Revenue | ₹418 Cr |
|---|---|
| Net Profit | ₹120 Cr |
| EPS (Basic) | ₹2.13 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
1. Contract Research Development & Manufacturing Services (CRDMO)-83.4% 2. Speciality Ingredients-16.6%
Anthem Biosciences Limited is trading at ₹800.75, with a market capitalisation of ₹46,303 Cr.
Anthem Biosciences Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Anthem Biosciences Limited has a P/E of 77.5 and a return on equity of 19.45%.
In Q1 FY27, Anthem Biosciences Limited reported revenue of ₹418 Cr and net profit of ₹120 Cr, with basic EPS of ₹2.13 (consolidated, parsed from the company's exchange filing).